Ophthotech acquires Biogen/PDL license for macular degeneration treatment
CAMBRIDGE, Mass. and REDWOOD CITY, Calif. Biogen Idec and PDL BioPharma have licensed the antibody volociximab to treat age-related macular degeneration to Ophthotech, according to published reports.
The terms of the deal were not disclosed, but the deal gives both Biogen and PDL an equity position in Ophthotech, plus any milestone or royalty payments based on development goals or product sales. In return, Ophthotech gains global development and commercial rights to all ophthalmic uses of volociximab.
Biogen and PDL had been jointly developing volociximab since 2005, when they both signed a collaboration agreement. That still continues in other indications. Among their more prominent efforts: The companies continue to explore whether the antibody can be used to treat solid tumor cancers.
Internet pharmacies make false claims regarding certification
SOUTH FLORIDA Federal regulators are receiving complaints from the Better Business Bureau and other professional groups after discovering that some Internet pharmacies are falsely claiming to be certified by their organizations, according to South Florida’s Sun-Sentinel.
The pharmacies are stating that they are located in Canada and are therefore offering cheaper prices on drugs to its customers, many of whom are Florida’s elderly. Customers started complaining after they wither did not receive their medications or they got drugs that appeared questionable.
One of the companies that the Internet pharmacies claim to be certified by is PharmacyChecker.com. Over the last 18 months, PharmacyChecker has received about 100 complaints from customers who thought they certified the websites.
The Internet pharmacies are using fake logos and phone numbers to make them appear certified and legitimate to customers. The Canadian International Pharmacy Association, which has 25 member pharmacies that are government-licensed, has also been receiving several calls a week from American consumers about not receiving shipments from sites they thought were CIPA-approved.
The Federal Bureau of Investigation has started a special investigation of Internet pharmacy practices, including the trademark violations and other issues.
Amylin launches SymlinPen for Type 2 diabetes
SAN DIEGO Amylin Pharmaceuticals has released its new prescription device, the SymlinPen 120 and 60 pen-injector devices for administering the blood sugar controlling drug Symlin. The new devices feature simple, fixed dosing to improve mealtime glucose control.
The SymlinPen 120 features fixed dosing to deliver 60 or 120 micrograms of Symlin per dose. The SymlinPen 60 features fixed dosing to deliver 15, 30, 45, or 60 micrograms of Symlin per dose. Both pen-injector devices can be conveniently stored at room temperature not to exceed 86 degrees F after first use.
“Symlin offers enhanced blood glucose control with potential weight loss for patients with diabetes using mealtime insulin, enabling them to do more to manage their diabetes,” said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. “The convenience of the new SymlinPen with simple, fixed dosing will make it easier for these patients using multiple daily injections to start and stay with Symlin.”